Lifotronic is a national high-tech enterprise committed to the research, development, production, marketing, sales and service of a wide range of treatment and rehabilitation equipment, in vitro diagnostic devices and reagents. The company is highly market oriented and mainly drivenby technology innovations.
Lifotronic was listed on SSE STAR Market on November 5, 2019. (Stock symbol: Lifotronic Technology, Stock code: 688389).
Lifotronic won the first place of National Science and Technology Progress Award as well as an Outstanding Award of CAIA. The company also established an academician workstation that was accredited by six ministries of China central government, a Guangdong provincial engineering technology research center, a Shenzhen municipal engineering technology research center, a Shenzhen municipal engineering laboratory, a Shenzhen municipal enterprise technology center as well as a postdoctoral innovation practicebase. In addition, Lifotronic has undertaken more than 20 R&D and industrialization projects at national, provincial and urban levels respectively.
In the treatment and rehabilitation sector, Lifotronic provides multiple clinical disciplines with professional and customized solutions based on its diversified technologies and products.
As for in vitro diagnosis, Lifotronic develops independently a full range of devices and reagents on itsmethodology platforms of electrochemiluminescence, immunoturbidimetry, liquid chromatography, immunofluorescence, hemagglutination mechanics and molecular diagnosis.
Lifotronic has built over the last decade a state-of-the-art system for the research, development, manufacturing, sales, service and quality control of medical devices. So far, its products have been installed and used in more than 15,000 hospitals, among them over 1,600 are tertiary, making Lifotronic a reliable supplier for hospitals across all levels.
| Full name | Shenzhen Lifotronic Technology Co., Ltd. |
|---|---|
| Abbreviations | Lifotronic |
| Code | 688389 |
| Founded | 2008-01-16 |
| Listing | 2019-11-05 |
| Domicile | Shenzhen |
| bod@lifotronic.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.34 | 0.26 | 0.21 |
| R&D expenditure as a % of operating revenue | 18.66% | 18.44% | 20.61% |
| Operating Revenue | 553.82 | 422.64 | 323.43 |
| Net Income | 143.97 | 100.56 | 81.14 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 553.82 | 422.64 | 323.43 |
| Operating Costs | 216.70 | 166.92 | 130.76 |
| Operating Income | 156.53 | 113.13 | 89.65 |
| Pretax Income | 156.22 | 112.98 | 89.67 |
| Income Tax | 12.26 | 12.42 | 8.53 |
| Net Income | 143.97 | 100.56 | 81.14 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 957.62 | 891.82 | 582.93 |
| Non-current Assets-Total | 331.92 | 287.14 | 229.00 |
| Total Assets | 1,289.54 | 1,178.96 | 811.93 |
| Liabilities | |||
| Current Liabilities-Total | 132.69 | 101.82 | 107.84 |
| Non-current Liabilities-Total | 13.29 | 27.47 | 35.69 |
| Total Liabilities | 145.98 | 129.29 | 143.53 |
| Stockholder's Equity | |||
| Share Capital | 906.69 | 906.69 | 565.97 |
| Retained Profits | 236.26 | 142.98 | 102.42 |
| Minority Interests | 0.61 | - | - |
| Total Owners' Equity | 1143.56 | 1049.67 | 668.39 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 136.42 | 91.82 | 81.14 |
| Net Cash Flows-Investing | -57.45 | -66.01 | -58.21 |
| Net Cash Flows-Financing | -50.59 | 277.68 | -3.37 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 刘先成 | 122.35 | 28.98% |
| 深圳瀚钰生物科技合伙企业（有限合伙） | 34.17 | 8.09% |
| 深圳瑞源成健康产业投资管理中心（有限合伙） | 29.46 | 6.98% |
| 深圳瑞普医疗技术研究所（有限合伙） | 28.84 | 6.83% |
| 曾映 | 18.81 | 4.46% |
| 胡明龙 | 18.81 | 4.46% |
| 徐岩 | 12.54 | 2.97% |
| 北京华泰瑞合医疗产业投资中心（有限合伙） | 10.99 | 2.6% |
| 深圳市创新投资集团有限公司 | 10.01 | 2.37% |
| 深圳市红土孔雀创业投资有限公司 | 8.59 | 2.03% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.